Table 1.
Sites for toxicology attrition. Based on experience from DuPont-Merck and Bristol-Myers Squibb, 1993–2006. Information kindly provided by B. D. Car, Bristol-Myers Squibb.
| Target organ or tissue | % of all advanced moleculesa |
|---|---|
| Cardiovascular | 27.3 |
| Liver | 14.8 |
| Teratogenicity | 8.0 |
| Hematologic | 6.8 |
| Central and peripheral nervous system | 6.8 |
| Retina | 6.8 |
| Mutagenicity/clastogenicity | 4.5 |
| Reproductive toxicity | 4.5 |
| Gastrointestinal/pancreatic | 3.4 |
| Muscle | 3.4 |
| Carcinogenicity | 3.4 |
| Lung | 2.3 |
| Acute death (unspecified cause) | 2.3 |
| Renal | 2.3 |
| Irritant | 2.3 |
| Skeletal (arthritis/bone development) | 1.1 |
a
Total = 100%.